Verzenio (Abemaciclib): A Complete Guide to its Use in Breast Cancer Treatment
Navigating breast cancer treatment can feel overwhelming, and understanding your options is crucial. Verzenio (abemaciclib) is a medication that has become an increasingly critically important part of treatment plans for several types of breast cancer. Here’s a detailed look at what you need to no, presented in a way that’s easy to understand.
What is Verzenio and How Does it Work?
Verzenio belongs to a class of drugs called CDK4/6 inhibitors. Essentially, it works by blocking certain proteins that promote the growth of cancer cells. By inhibiting these proteins, Verzenio can slow or stop the spread of cancer. It’s typically used in combination with other breast cancer treatments, like hormone therapy.
Approved Uses: A Growing Spectrum of Care
Initially approved for advanced or metastatic breast cancer,Verzenio’s applications have expanded considerably over the years. Here’s a breakdown of the conditions it’s currently approved to treat:
Advanced or metastatic HR+, HER2- Breast Cancer: This was the initial approval, and Verzenio is used in combination with hormone therapy for this type of cancer that has spread. Early-Stage, High-Risk HR+, HER2- Breast Cancer: Verzenio is now approved as an adjuvant therapy – meaning it’s given after surgery – for patients with a high risk of recurrence. This is a significant advancement,offering a chance to prevent the cancer from returning.
Node-Positive, High-Risk Early-Stage HR+, HER2- Breast Cancer: The indication has been broadened to include those with cancer that has spread to the lymph nodes, further expanding the number of people who may benefit.
Understanding HR+, HER2- – what Do These terms Mean?
You’ve likely heard these terms when discussing your breast cancer. Let’s break them down:
HR+ (Hormone Receptor Positive): This means your cancer cells have receptors for estrogen or progesterone. These hormones can fuel cancer growth, so treatments often aim to block these hormones.
HER2- (Human Epidermal Growth Factor Receptor 2 Negative): HER2 is a protein that can promote cancer growth. HER2-negative means your cancer cells don’t have high levels of this protein.
Verzenio is specifically designed for breast cancers that are HR+ and HER2-.
The Evolution of Verzenio’s Approvals: A Timeline of Progress
The journey of Verzenio reflects ongoing research and a commitment to improving breast cancer care.
2017: Initial FDA approval for advanced or metastatic HR+, HER2- breast cancer.
2018: expanded approval for use as an initial treatment for advanced breast cancer.
2021: Breakthrough approval as the first CDK4/6 inhibitor for certain people with high-risk, early-stage HR+, HER2- breast cancer.
2023: Further broadened indication to include node-positive, high-risk early-stage HR+, HER2- breast cancer.
2024: Recent studies have demonstrated that Verzenio can increase overall survival in patients with HR+, HER2- metastatic breast cancer, solidifying its place in treatment protocols.
What to Expect: Side Effects and Management
Like all medications, Verzenio can cause side effects. Common side effects include:
Diarrhea
Fatigue
Nausea
Decreased appetite
* Low blood cell counts
I’ve found that managing these side effects proactively is key. Your healthcare team can provide guidance on medications and lifestyle adjustments to help you cope. It’s crucial to report any side effects you experience so they can be addressed